Dynavax releases Phase 1b hepatitis B vaccine trial results
Dynavax said that the candidate vaccine, DV-601, is designed to induce an immune response against HBV-infected cells and if proven to be safe and effective, may offer an
Innovent Biologics and Daiichi Sankyo have signed an exclusive agreement to commercialise Vanflyta (quizartinib), an oral type II FLT3 inhibitor, in China.
The preclinical collaboration is being conducted with Marina Konopleva, associate professor in the Department of Leukemia at MD Anderson Cancer Center. The research collaboration will focus on characterizing